BMS ‘bet’ with Celgene shareholders in balance after CAR-T refileBristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a Share XBMS ‘bet’ with Celgene shareholders in balance after CAR-T refilehttps://pharmaphorum.com/news/bms-2/
CHMP gives nod to GSK’s BCMA drug Blenrep for myelomaGlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light Share XCHMP gives nod to GSK’s BCMA drug Blenrep for myelomahttps://pharmaphorum.com/news/chmp-gives-nod-to-gsks-bcma-drug-blenrep-for-myeloma/
FDA experts okay GSK’s multiple myeloma drug despite safety worriesGlaxoSmithKline’s potential first-in-class multiple myeloma drug belantamab mafodotin has taken a step closer to US approval after unanimous backing from a panel of expert advisers convened Share XFDA experts okay GSK’s multiple myeloma drug despite safety worrieshttps://pharmaphorum.com/news/fda-experts-okay-gsks-multiple-myeloma-drug-despite-safety-worries/
FDA reviewer warns of eye trouble with GSK’s myeloma ADCGlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for Share XFDA reviewer warns of eye trouble with GSK’s myeloma ADChttps://pharmaphorum.com/news/fda-reviewer-warns-of-eye-trouble-with-gsks-myeloma-adc/
Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomaSanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells Share XKiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomahttps://pharmaphorum.com/news/sanofi-to-develop/
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
Sanofi’s multiple myeloma drug approved in EUSanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Share XSanofi’s multiple myeloma drug approved in EUhttps://pharmaphorum.com/news/sanofis-multiple-myeloma-drug-approved-in-eu/
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trialsBristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough Share XCompetition heats up in BCMA CAR-T as J&J, BMS update myeloma trialshttps://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/
Sanofi builds case for Sarclisa, challenging J&J’s DarzalexSanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Share XSanofi builds case for Sarclisa, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-builds-case-for-sarclisa-challenging-jjs-darzalex/
